We describe two improved assays for in vitro and in vivo screening of inhibitors and chemicals for antimalarial activity against blood stages of the rodent malaria parasite, Plasmodium berghei. These assays are based on the determination of bioluminescence in small blood samples that is produced by reporter parasites expressing luciferase. Luciferase production increases as the parasite develops in a red blood cell and as the numbers of parasites increase during an infection. In the first assay, in vitro drug luminescence (ITDL) assay, the in vitro development of ring-stage parasites into mature schizonts in the presence and absence of candidate inhibitor(s) is quantified by measuring luciferase activity after the parasites have been allowed to mature into schizonts in culture. In the second assay, the in vivo drug luminescence (IVDL) assay, in vivo parasite growth (using a standard 4-day suppressive drug test) is quantified by measuring the luciferase activity of circulating parasites in samples of tail blood of drug-treated mice.
Malaria Plasmodium bergheiBlood stages, drug screening Luciferase Luminescence Mice
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Jing-wen Lin was supported by the China Scholarship Council (CSC).
Smilkstein M (2004) Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48:1803–1806PubMedCrossRefGoogle Scholar
Baniecki ML et al (2007) High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51:716–723PubMedCrossRefGoogle Scholar
Gamo FJ et al (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465:305–310PubMedCrossRefGoogle Scholar
Plouffe D et al (2008) In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA 105:9059–9064PubMedCrossRefGoogle Scholar
Rastu-Kapur S et al (2008) Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat Chem Biol 4:203–213CrossRefGoogle Scholar
Rottmann M et al (2010) Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180PubMedCrossRefGoogle Scholar
Franke-Fayard B et al (2008) Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. Int J Parasitol 38:1651–1662PubMedCrossRefGoogle Scholar
Peters W (1987) Chemotherapy and drug resistance in malaria. Academic, LondonGoogle Scholar
Janse CJ et al (1994) Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei rodent model. Int J Parasitol 24:589–594PubMedCrossRefGoogle Scholar
Sanchez BA et al (2004) Plasmodium berghei parasite transformed with green fluorescent protein for screening blood schizontocidal agents. Int J Parasitol 34:485–490PubMedCrossRefGoogle Scholar
Franke-Fayard B et al (2004) A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol 137:23–33PubMedCrossRefGoogle Scholar
Spaccapelo R et al (2010) Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria. Am J Pathol 176:205–217PubMedCrossRefGoogle Scholar
Janse CJ, Waters AP (1995) Plasmodium berghei: the application of cultivation and purification techniques to molecular studies of malaria parasites. Parasitol Today 11:138–143PubMedCrossRefGoogle Scholar
Franke-Fayard B et al (2005) Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA 102:11468–11473PubMedCrossRefGoogle Scholar
Gilks CF et al (1989) Host diet in experimental rodent malaria: a variable which can compromise experimental design and interpretation. Parasitology 98(Pt 2):175–177PubMedCrossRefGoogle Scholar
Chen L, Sendo F (2001) Cytokine and chemokine mRNA expression in neutrophils from CBA/NSlc mice infected with Plasmodium berghei ANKA that induces experimental cerebral malaria. Parasitol Int 50:139–143PubMedCrossRefGoogle Scholar
de Souza JB, Riley EM (2002) Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 4:291–300PubMedCrossRefGoogle Scholar